Enanta Pharmaceuticals
ENTA
ENTA
146 hedge funds and large institutions have $869M invested in Enanta Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $1.02B → $869M (-$153M)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
146
Holding in Top 10
1
Calls
$10.6M
Puts
$176K
Top Buyers
| 1 | +$12.4M | |
| 2 | +$6.27M | |
| 3 | +$6.16M | |
| 4 |
CC
Commodore Capital
New York
|
+$5.58M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$5.12M |
Top Sellers
| 1 | -$46.5M | |
| 2 | -$24.3M | |
| 3 | -$11.6M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3.78M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.09M |